Sakai, T <br/><br/>
Niacin, but not gemfibrozil, selectively increases LP-AI, a cardioprotective subfraction of HDL, in patients with low HDL cholesterol.  [electronic resource] 

 -  Arteriosclerosis, thrombosis, and vascular biology  Nov 2001 
 - 1783-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1524-4636 
<br/><br/><label>Standard No.: </label>10.1161/hq1001.096624  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Apolipoprotein A-I--biosynthesis<br/>Apolipoprotein A-II--blood<br/>Arteriosclerosis--drug therapy<br/>Cholesterol, HDL--metabolism<br/>Dose-Response Relationship, Drug<br/>Double-Blind Method<br/>Gemfibrozil--pharmacology<br/>Hepatocytes--metabolism<br/>Humans<br/>Hypolipidemic Agents--pharmacology<br/>Lipids--blood<br/>Lipoproteins, HDL--chemistry<br/>Niacin--pharmacology<br/>Tumor Cells, Cultured